GlassScriptPhysician profile
Su Hlaing
NPI 1437739562
$1,364.03
in general payments reported to CMS, 2019-2025
12 companies · $582 in 2025
The $582 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.62 · 2022: $26.92 · 2023: $367 · 2024: $372 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $303.37 | 2023-2025 | |
| Gilead Sciences, INC. | $299.23 | 2023-2024 | Epclusa |
| Novo Nordisk INC | $164.12 | 2024-2025 | Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Lilly USA, LLC | $121.97 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Viiv Healthcare Company | $118.93 | 2024 | Apretude, Dovato |
| Abbott Laboratories | $113.28 | 2025 | Freestyle Libre 3 |
| Shield Therapeutics INC | $27.87 | 2025 | |
| Pfizer INC. | $26.15 | 2025 | |
| Dynavax Technologies Corporation | $26.05 | 2024 | Heplisav-B |
| Merck Sharp & Dohme LLC | $22.44 | 2025 | Gardasil 9, M-M-R II, Enflonsia |
| Glaxosmithkline, LLC. | $15.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Su Hlaing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.